Illumina: Competitive Threats Priced In

Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition....

Seeking Alpha - 4/10/2026 3:14:49 AM More News for ILMN
Stock Analysis for ILMN
Related Stocks: